|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
This is a pilot study to assess the safety, pharmacokinetics and effectiveness of PINTA 745 or placebo in treating protein energy wasting (PEW) in patients receiving maintenance hemodialysis (MHD).
100 Clinical Results associated with Pinta Biotherapeutics, Inc.
0 Patents (Medical) associated with Pinta Biotherapeutics, Inc.
100 Deals associated with Pinta Biotherapeutics, Inc.
100 Translational Medicine associated with Pinta Biotherapeutics, Inc.